Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Host: Joshua E. Reuss, MD
\n\n\n \n
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.